All In Biotech

Drug Trial Radar · NCT05646862

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Jun 7, 2023

Primary completion

Nov 13, 2026

Study completion Mar 30, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy. Enrollment for the main study is now complete.

Conditions

  • Breast Cancer

Interventions

  • InavolisibDrug

    Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle of main study and sub-study.

  • FulvestrantDrug

    Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.

  • AlpelisibDrug

    Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.

  • BupropionDrug

    Participants will be administered bupropion PO on Day -3 and Day 12 of Cycle 1 of the sub-study.

  • OmeprazoleDrug

    Participants will be administered omerprazole PO on Day -4 and Day 11 of Cycle 1 of sub-study.

  • MidazolamDrug

    Participants will be administered midazolam PO on Day -4 and Day 11 of Cycle 1 of sub-study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blinded Independent Central Review (BICR)-Assessed Progression Free Survival (PFS)Time frame: From randomization until disease progression or death due to any cause (up to approximately 64 months)
  2. Sub-study: Maximum observed Drug Concentration (Cmax) for MidazolamTime frame: Day -4 and -3 of Cycle (C) 1, Day (D) 11 and C1D12. A cycle is 28 days.
  3. Sub-study: Cmax for BupropionTime frame: Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.
  4. Sub-study: Cmax for OmeprazoleTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
  5. Sub-study: Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUC [0-last]) for MidazolamTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
  6. Sub-study: AUC (0-last) for BupropionTime frame: Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.
  7. Sub-study: AUC (0-last) for OmeprazoleTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
  8. Sub-study: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) for MidazolamTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
  9. Sub-study: AUC (0-infinity) for BupropionTime frame: Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.
  10. Sub-study: AUC (0-infinity) for OmeprazoleTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.

Locations

210 sites in 20 countries. Site status is shown where the registry gives one.

  • Marin Cancer Care Inc

    Greenbrae, California · Withdrawn

  • Cancer Blood and Specialty Clinic

    Los Alamitos, California · Active not recruiting

  • Los Angeles Cancer Network

    Los Angeles, California · Active not recruiting

  • University of California, Irvine Medical Center

    Orange, California · Withdrawn

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Active not recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Completed

  • Banner MD Anderson Cancer Center

    Greeley, Colorado · Withdrawn

  • Eastern CT Hematology and Oncology Associates

    Norwich, Connecticut · Withdrawn

  • Cancer Care Centers of Brevard

    Palm Bay, Florida · Withdrawn

  • Cleveland Clinic Florida

    Weston, Florida · Active not recruiting

  • Grady Health System

    Atlanta, Georgia · Active not recruiting

  • Midtown West Medical

    Atlanta, Georgia · Active not recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute at Emory Saint Joseph's Hospital

    Atlanta, Georgia · Active not recruiting

  • University of Louisville Hospital

    Louisville, Kentucky · Withdrawn

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute.

    Detroit, Michigan · Withdrawn

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Completed

  • Minnesota Oncology Hematology

    Saint Paul, Minnesota · Active not recruiting

  • MD Anderson Cancer Center at Cooper

    Camden, New Jersey · Withdrawn

  • Novant Health Presbyterain Medical Center

    Charlotte, North Carolina · Withdrawn

  • Novant Health Forsyth Medical Center

    Winston-Salem, North Carolina · Withdrawn

  • Gabrail Cancer Center

    Canton, Ohio · Withdrawn

  • Asante Rogue Regional Medical Center

    Medford, Oregon · Completed

  • Bryn Mawr Hospital

    Bryn Mawr, Pennsylvania · Withdrawn

  • St. Lukes Hospital and Health Network

    Easton, Pennsylvania · Withdrawn

  • Paoli Memorial Hospital

    Paoli, Pennsylvania · Withdrawn

  • Abramson Cancer Center Chester County Hospital

    West Chester, Pennsylvania · Withdrawn

  • Lankenau Medical Center, Cancer Center

    Wynnewood, Pennsylvania · Withdrawn

  • Main Line Health System

    Wynnewood, Pennsylvania · Withdrawn

  • WellSpan Oncology Research

    York, Pennsylvania · Withdrawn

  • Texas Oncology West

    Amarillo, Texas · Withdrawn

  • Texas Oncology - Dallas Presbyterian Hospital

    Dallas, Texas · Active not recruiting

  • Texas Tech University Health Sciences Center

    El Paso, Texas · Withdrawn

  • Texas Oncology (Flower Mound) - USOR

    Flower Mound, Texas · Withdrawn

  • The Center for Cancer and Blood Disorders - Fort Worth

    Fort Worth, Texas · Withdrawn

  • Lumi Research

    Kingwood, Texas · Withdrawn

  • Texas Oncology McKinney

    McKinney, Texas · Withdrawn

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington · Withdrawn

  • Centro de Investigaciones Médicas y Desarrollo LC S.R.L

    Buenos Aires, Argentina · Completed

Showing 40 of 210 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.